Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 12 sources · 4 days · First seen 6 days ago · Last updated 2 days ago

CVM mandates Centaurus tender offer for Oncoclínicas

Overview

The Brazilian Securities and Exchange Commission (CVM) has unanimously decided that Centaurus Capital must launch a public tender offer (OPA) for shares of Oncoclínicas (ONCO3). This ruling reverses the previous stance of the CVM’s technical department, which had argued that the November 2024 reorganization of the Josephina funds did not trigger a new acquisition.

The CVM board’s decision supports the claims made by minority shareholders, led by Latache Capital, who argued that the reorganization triggered a ‘poison pill’ clause in the company’s bylaws. This clause mandates a tender offer if an investor’s stake exceeds 15%. The dispute centered on the Josephina III fund, a vehicle linked to Centaurus, which ended up directly holding a 31.83% stake in Oncoclínicas.

Centaurus Capital continues to contest the decision, maintaining that its economic interest in the company predates the IPO and that the reorganization was merely a structural change in ownership rather than a new acquisition. In response, Centaurus has initiated arbitration through the B3 Arbitration Chamber. Additionally, the Brazilian Association of Investment, Credit, and Consumption (Abraicc) has announced its intention to file a lawsuit to enforce the mandated offer.

Entities

Goldman Sachs · CVM · Centaurus Capital · Oncoclínicas · Comissão de Valores Mobiliários

Claims

What the coverage asserts, and how many sources carry each claim.

[● 3 SOURCES] The CVM board unanimously decided that Centaurus must conduct a public tender offer (OPA) for Oncoclínicas shares. guiadoinvestidor.com.br · www.infomoney.com.br · veja.abril.com.br
[● 3 SOURCES] The CVM board reversed the previous understanding held by its technical department. guiadoinvestidor.com.br · www.infomoney.com.br · veja.abril.com.br
[● 2 SOURCES] The transaction is estimated by the market to be worth approximately R$ 6.5 billion. guiadoinvestidor.com.br · oglobo.globo.com
[● 2 SOURCES] Centaurus has initiated arbitration proceedings through the B3 Arbitration Chamber. guiadoinvestidor.com.br · oglobo.globo.com
[● 2 SOURCES] The company's bylaws include a 'poison pill' clause requiring a tender offer if an investor exceeds a 15% ownership stake. noticias.uol.com.br · veja.abril.com.br
[○ 1 SOURCE] Oncoclínicas has a total liability of R$ 5.1 billion. www.infomoney.com.br
[○ 1 SOURCE] Latache Capital argues that the 2024 corporate reorganization triggered the mandatory tender offer requirement. guiadoinvestidor.com.br
[○ 1 SOURCE] The Brazilian Association of Investment, Credit, and Consumption (Abraicc) plans to file a legal action to compel the tender offer. oglobo.globo.com

Timeline

2 days ago

[BUSINESS] 11 sources
CVM mandates Centaurus Capital to launch tender offer for Oncoclínicas
The CVM unanimously ruled that Centaurus Capital must conduct a tender offer for Oncoclínicas, potentially worth R$ 6.5 billion, following a dispute over shareholder protection clauses.
6 days ago

[BUSINESS] 5 sources
CVM to judge Oncoclínicas tender offer appeal on August 25
The CVM will judge an appeal on August 25 regarding whether Oncoclínicas must conduct a mandatory tender offer following a fund reorganization involving Centaurus Capital.

Sources

bmcnews.com.br · brasil247.com · fatoamazonico.com.br · guiadoinvestidor.com.br · hopkinsmedicine.org · infomoney.com.br · mobile.valor.com.br · moneytimes.com.br · oglobo.globo.com · sbtnews.sbt.com.br · seudinheiro.com · veja.abril.com.br

This summary has been updated 2 times: see revision history